Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA5269619
Max Phase: Preclinical
Molecular Formula: C23H24N2O2
Molecular Weight: 360.46
Associated Items:
ID: ALA5269619
Max Phase: Preclinical
Molecular Formula: C23H24N2O2
Molecular Weight: 360.46
Associated Items:
Canonical SMILES: O=C(OCCN1CCN(c2ccccc2)CC1)c1cccc2ccccc12
Standard InChI: InChI=1S/C23H24N2O2/c26-23(22-12-6-8-19-7-4-5-11-21(19)22)27-18-17-24-13-15-25(16-14-24)20-9-2-1-3-10-20/h1-12H,13-18H2
Standard InChI Key: AIMIZAJPEKRFPH-UHFFFAOYSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 360.46 | Molecular Weight (Monoisotopic): 360.1838 | AlogP: 3.82 | #Rotatable Bonds: 5 |
Polar Surface Area: 32.78 | Molecular Species: NEUTRAL | HBA: 4 | HBD: 0 |
#RO5 Violations: 0 | HBA (Lipinski): 4 | HBD (Lipinski): 0 | #RO5 Violations (Lipinski): 0 |
CX Acidic pKa: | CX Basic pKa: 7.07 | CX LogP: 4.72 | CX LogD: 4.56 |
Aromatic Rings: 3 | Heavy Atoms: 27 | QED Weighted: 0.65 | Np Likeness Score: -1.20 |
1. Aranha CMSQ, Reiner-Link D, Leitzbach LR, Lopes FB, Stark H, Fernandes JPS.. (2023) Multitargeting approaches to cognitive impairment: Synthesis of aryl-alkylpiperazines and assessment at cholinesterases, histamine H3 and dopamine D3 receptors., 78 [PMID:36542960] [10.1016/j.bmc.2022.117132] |
Source(1):